Abstract 1245P
Background
Specific requirements of the minimum number of harvested lymph nodes for accurate nodal staging in small intestinal tumors are sparse as there is a probability that false-negative lymph nodes remain. The aim of this study is to establish a histologic-type-specific nodal staging score (NSS) model for the specific requirements of lymph nodes in small intestinal tumors by taking potential false-negative lymph nodes into consideration.
Methods
Small intestinal tumors with complete follow-up and examined/positive lymph nodes data were retrieved using the Surveillance, Epidemiology, and End Results program. Using a beta-binomial model, the probability of lymph nodes with occult disease and the NSS model were established.
Results
A total of 7649 small intestinal tumors were retrieved, including 3789 carcinoid cases, 2467 adenocarcinoma cases, 718 neuroendocrine carcinoma cases, 502 sarcoma cases, and 173 others. To reach a 0.05 false-negative probability, the minimum number of lymph nodes was 10 in carcinoid tumors, 11 in adenocarcinoma, 12 in neuroendocrine carcinoma, 7 in sarcoma, and 16 in others. Distinct NSS curves were presented among each histologic type of small intestinal tumors. The NSS of neuroendocrine carcinoma indicated that a higher number of lymph nodes was required to enable the correct staging of lymph nodes compared to other types of small intestinal tumors. The prognostic values of NSS quartiles were validated.
Conclusions
The minimum required number of examined lymph nodes varied in each histologic type of small intestinal tumors. The NSS improved the adequacy of nodal staging for patients for clinical interpretation and decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1794P - Prognostic role of metastatic site in patients with de novo metastatic prostate cancer: A population-based analysis in new hormonal agents era
Presenter: Emre Yekeduz
Session: Poster session 14
1795P - China ARCHES: A multicenter phase III randomized double-blind placebo (PBO)-controlled efficacy and safety trial of enzalutamide (ENZA) + androgen deprivation therapy (ADT) vs PBO + ADT in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC)
Presenter: Gongqian Zeng
Session: Poster session 14
1796P - Real-world analysis of metastatic hormone-sensitive prostate cancer: Are randomized clinical trials more trustworthy? Insights from PIONEER, the European network of excellence for big data in prostate cancer
Presenter: Juan Gómez Rivas
Session: Poster session 14
1797P - Application of novel machine learning model in [68Ga] Ga-PSMA-11 PET/CT: Predicting survival in oligometastatic prostate cancer patients
Presenter: Mikaela Dell'Oro
Session: Poster session 14
1800P - Differential tumor gene-expression profiling of patients (pts) with de-novo metastatic castration-sensitive prostate cancer (dn-mCSPC) versus (vs.) mCSPC relapsing after prior localized therapy (PLT-mCSPC)
Presenter: Vinay Mathew Thomas
Session: Poster session 14
1803P - Phase I/II study of bavdegalutamide, a PROTAC androgen receptor (AR) degrader in metastatic castration-resistant prostate cancer (mCRPC): Radiographic progression-free survival (rPFS) in patients (pts) with <italic>AR</italic> ligand-binding domain (LBD) mutations
Presenter: Daniel Petrylak
Session: Poster session 14